Today’s Paper
Health Newspapers

For how we live.

EXPLAINER

The 'digital pill' that reports when you swallow it, and what it can't prove

Abilify MyCite embeds a sensor in an antipsychotic tablet to log each dose to an app. Nearly a decade on, its own FDA label still says it has not been shown to improve whether patients take their medicine.

By Mac Giles
Published September 18, 2026 · 4 min read

Abilify MyCite is an antipsychotic pill — the generic drug aripiprazole — with a grain-sized sensor baked into the tablet that signals a skin patch and a smartphone app once stomach fluid dissolves it, so software can record that the dose was actually swallowed [s1][s2]. Nearly a decade after the US Food and Drug Administration approved it as the first such "digital pill," the product's own FDA label still states plainly what the pitch implies but the trials never demonstrated: there is no established evidence it makes patients take their medicine any more reliably [s2].

The FDA approved the drug-device combination in November 2017 for adults with schizophrenia, bipolar I disorder, and as an add-on treatment for major depressive disorder — conditions where stopping medication is common and consequential [s1]. The Ingestible Event Marker inside each tablet has no battery: it is powered by contact with stomach fluid, emits a signal to a patch worn on the torso, and that patch relays a timestamp to an app the patient, and anyone they authorise, can see [s2].

What the label actually claims

Read the indication and the promise seems obvious — a pill that proves it was taken should improve adherence. The FDA-approved labeling refuses that inference in two sentences. Under Limitations of Use it states: "The ability of ABILIFY MYCITE to improve patient compliance or modify aripiprazole dosage has not been established," and "The use of ABILIFY MYCITE to track drug ingestion in 'real-time' or during an emergency is not recommended because detection may be delayed or not occur" [s2]. In other words, the system was authorised to record ingestion, not shown to increase it, and it is not reliable enough to act on in the moment — detection can lag, or fail to register at all [s2].

That is an unusually candid gap between a technology's evident purpose and its proven effect, and it has not closed. A device can be safe and do exactly what it says — log a swallow — without any evidence that logging changes the behaviour it is meant to fix.

The evidence that exists, and who paid for it

The strongest published support is not a randomised trial. A retrospective claims-database analysis, funded by the drug's manufacturer Otsuka and co-authored by a company employee, matched people who started aripiprazole-with-sensor to similar patients on ordinary antipsychotics and reported that the sensor group accumulated 41% more days of antipsychotic supply over six months and had fewer psychiatric visits [s3]. The authors call the findings "preliminary" and say larger studies are "warranted" before they should inform clinical practice or coverage [s3].

Those caveats matter, and this site treats a manufacturer's own outcome data as a company claim, not an independent verdict. An observational comparison cannot separate the device from the person: someone who agrees to swallow a monitored pill and wear a patch may already be more engaged with treatment than someone who declines, so the group can look more adherent without the sensor having changed anything. Only a randomised design controls for that, and the pivotal evidence behind the label did not establish an adherence benefit [s2].

The surveillance question sitting underneath

A pill that reports to an app raises a problem the smart pill bottles and cap sensors and connected inhalers covered here also raise, but sharpened by its population. Abilify MyCite is aimed partly at serious mental illness, where questions of insight, consent and coercion are most acute — and where a tool that lets a clinician or family member watch a timestamped feed of whether someone took their antipsychotic can shade from support into monitoring. The health data these consumer-facing systems generate also tends to fall outside the clinical privacy laws patients assume protect it. The ethical weight of that trade-off would be easier to justify if the adherence benefit were proven; the label says it is not [s2].

Why it matters

Non-adherence to antipsychotics is a real driver of relapse and hospitalisation, and a reliable way to measure it would be genuinely useful for research and, potentially, care. But "measures ingestion" and "improves ingestion" are different claims, and the digital pill has only ever been authorised for the first [s2]. A reader — or a clinician weighing it — should hold the marketing to the label: this is a sensor that logs a dose, not a proven fix for the reason doses get missed.

What to watch

Whether any adequately powered randomised trial tests the adherence claim head-on; whether uptake stays marginal, as it has, when the core benefit is unproven and the monitoring is intrusive; and how consent is handled when the person being tracked has a condition that can impair the very judgement the tracking assumes.

This article is informational and is not medical advice.

Sources

Sources

  1. Drugs@FDA: ABILIFY MYCITE (aripiprazole tablets with sensor), NDA 207202 — U.S. Food and Drug Administration , November 13, 2017
  2. ABILIFY MYCITE (aripiprazole tablets with sensor) prescribing information — Limitations of Use — U.S. Food and Drug Administration (DailyMed) , April 2, 2026
  3. Real-World Evidence of Aripiprazole Tablets with Sensor: Treatment Patterns and Impacts on Psychiatric Healthcare Resource Utilization — ClinicoEconomics and Outcomes Research , June 22, 2023

More on

Topics

Related coverage